Thrombotic antiphospholipid syndrome (APS) is a complex immune-mediated thrombotic disorder, classified by laboratory features: persistent antiphospholipid antibodies (aPL), namely lupus anticoagulant (LA) and/or IgG/IgM anti-β2-glycoprotein I (aβ2GPI) and IgG/IgM anticardiolipin antibodies (aCL), together with thrombosis [1], with thrombocytopenia recently included again as a clinical criterion [2]. Here, CD40LG is linked to Thrombocytopenia.